Digene's Hybrid Capture II
This article was originally published in The Gray Sheet
Human papillomavirus test is more accurate than conventional Pap smear screening for identifying women with cervical disease, according to a study published in the Sept. 10 British Journal of Cancer and reported by Digene Sept. 13. The test was sufficiently sensitive to detect 95% of women with serious cervical disease while less than 5% of normal women tested positive, researchers found. In comparison, the Pap smear was able to detect only 79% of those with cervical disease. Conducted in the U.K. by the Imperial Cancer Research Fund, the study included 2,988 women over 35 who were given the HPV test and Pap screening simultaneously. The Hybrid Capture II was approved by FDA in March for use as an adjunct to the Pap smear for cervical cancer screening. Investigators suggest the findings support use of the test for primary screening
You may also be interested in...
ASTM International is proposing a new standard that will provide a cleaning agent formula for removing dried blood from stainless steel medical devices.
Executive appointments at MyoKardia, Scancell Holdings and Sutro Biopharma
The merger between Mylan and Pfizer’s Upjohn unit finally concluded on 16 November 2020, giving Viatris the go ahead for business. The newly-established company has announced receiving tentative approval for its 10mg pediatric dolutegravir tablets from the FDA under the PEPFAR program.